Factor IX (FIX), a circulating serine protease that serves as an essential component of the blood coagulation pathway, has been shown to increase with age in humans. We show here that murine FIX mRNA and activity levels also increase with age. Furthermore, one form of hemophilia B, hemophilia B Leyden, which is caused by mutations within the promoter region of the FIX gene, has a distinct age-dependent phenotype. To determine the source of the age-related increases in FIX gene expression, we have analyzed the regulation of the normal FIX gene promoter and FIX Leyden gene promoter with the + 13 mutation during aging by generating LOTTING FACTOR IX (FIX), a circulating serine protease, is a key component of the coagulation cascade.' It is synthesized primarily by hepatocytes starting early in and has been shown to increase in elderly hum a n~.~ Failure to synthesize functional FIX at physiologic levels results in the bleeding disorder known as hemophilia B.6 In all hemophilia B patients analyzed to date, the disease is a consequence of mutations within the FIX gene that result in the production either of a defective product or a complete absence of product." These mutations, which vary from large deletions7 to point mutation^,^.^ occur primarily within coding portions of the FIX gene,' with the most frequent and severe clustered within the exons for the catalytic domain of the e n~y m e .~.~ Intriguingly, patients with one variant of hemophilia B, hemophilia B Leyden, display a unique, agedependent phenotype.'" Prepubescent males with the Leyden phenotype have decreased clotting activity because of insufficient FIX synthesis. After puberty, FIX activity gradually increases with age, reaching approximately 60% of adult normal levels in elderly patients with an associated amelioration of the symptoms of the disease.'" Interestingly, all Leyden patients have mutations within a small segment of the FIX promoter region immediately adjacent to the major transcription start site."."
LOTTING FACTOR IX (FIX), a circulating serine protease, is a key component of the coagulation cascade.' It is synthesized primarily by hepatocytes starting early in and has been shown to increase in elderly hum a n~.~ Failure to synthesize functional FIX at physiologic levels results in the bleeding disorder known as hemophilia B.6 In all hemophilia B patients analyzed to date, the disease is a consequence of mutations within the FIX gene that result in the production either of a defective product or a complete absence of product." These mutations, which vary from large deletions7 to point mutation^,^.^ occur primarily within coding portions of the FIX gene,' with the most frequent and severe clustered within the exons for the catalytic domain of the e n~y m e .~.~ Intriguingly, patients with one variant of hemophilia B, hemophilia B Leyden, display a unique, agedependent phenotype.'" Prepubescent males with the Leyden phenotype have decreased clotting activity because of insufficient FIX synthesis. After puberty, FIX activity gradually increases with age, reaching approximately 60% of adult normal levels in elderly patients with an associated amelioration of the symptoms of the disease.'" Interestingly, all Leyden patients have mutations within a small segment of the FIX promoter region immediately adjacent to the major transcription start site."."
The first Leyden patient identified had a T to A transversion at the -20 position" and, subsequently, patients with point mutations at -21, -5, -6, +6, +8, and + l 3 have been identified.9 It has been suggested that these mutations disrupt the binding of essential trans-acting DNA regulatory transgenic mice that contain the -189 to +21 bp promoter segment ligated to a chloramphenicol acetyttransferase reporter gene. We have established that the normal FIX promoter and the Leyden promoter transgenes are expressed in a tissue-specific manner in vivo. The normal FIX promoter transgene does not show any differences in the pattern of expression with age or sex of the organism, whereas the Leyden promoter transgene showed age-dependent malespecific expression. This is the first demonstration of the FIX Leyden phenotype in a transgenic mouse model. 0 1995 by The American Society of Hematology.
proteins, thereby decreasing FIX mRNA synthesis.'"'' This hypothesis is strengthened by clinical data showing that the severity of the Leyden phenotype can vary depending on the type of mutation (transversion or transition) at the same location in the promoter.I6 Five sequence-specific DNA binding proteins have been identified that bind to elements within the FIX promoter segment in vitro. These proteins include CAAT enhancer binding protein (C/EBPa),I4 liver nuclear factor 1 (NF-1L),l4 hepatocyte nuclear factor 4 (HNF-4)," androgen receptor (AR),I8 and D-site binding protein (DBP)." The +S and + l 3 Leyden mutations appear to disrupt the binding of CIEBPC~,~.'~ whereas the -20 and -26 mutations disrupt HNF-4 binding to human promoter fragments in vitro.''.'* In addition to these disruptions, the synergy between DBP and CIEBPa has been shown to compensate for the -5 m~tation.'~ The postpubertal increase in FIX activity in male Leyden patients has been suggested to be caused by androgens. This idea was supported by the observation that danazol, an androgen derivative, stimulates FIX activity in prepubescent Leyden male patients." Furthermore, afflicted individuals with another form of hemophilia B, hemophilia B Brandenburg (caused by a -26 mutation) do not exhibit postpubertal increases in FIX activity.]' This mutation has been shown to disrupt an HNF-4 binding site as well as that of an overlapping androgen-responsive element (ARE)." The identification of ARE within the FIX promoter directly links androgens with the upregulation of the FIX gene in Leyden patients. However, testosterone" and androgen receptor mRNAZ2 levels reach a maximum shortly after puberty, whereas FIX levels in Leyden patients continue to increase; hence it seems that the androgen stimulus cannot be the sole factor responsible for the age-specific increase in FIX activity seen in Leyden patients. Rather, it suggests that another age-dependent regulatory protein(s) must be involved in the regulation of the FIX Leyden gene. Thus, the mechanism of age-specific recovery in Leyden patients still remains elusive.
Therefore, to investigate, in vivo, the age-specific expression of the FIX Leyden promoter, we have prepared two separate fusion genes by linking either a normal -189 to +21 bp human FIX promoter or the same promoter containing the + 13 Leyden mutation to a chloramphenicol acetyltransferase (CAT) reporter gene ( Fig 1A) . Subsequently, 
AGCTTGGCGAGATTTTCAGGAGCTAAGGAAGCTAAA

MATERIALS AND METHODS
Tronygmic ctnimol.7. We chose to use the -189 to +2 I bp fragment of the human FIX promoter in the preparation of our fusion gene constructs. This selection was based on the demonstration by Crossley and Brownlee'" and Salier et al" of essentially comparable FIX promoter activity whether roughly 2,300 or 200 bp of 5' flanking DNA was incorporated into fusion genes, which were then expressed in HepG2 cells by transient transfections. Two chimeric genes were constructed (in pCATOO vector") that consisted of the human FIX promotor segment extending from bp -189 to +212' (equivalent to the shorter promoter of the earlier studies) ligated to the CAT reporter gene and SV40 polyadenylation site (Fig 1 A and B) . The first chimeric gene contained the normal promoter sequence and was constructed in our laboratory; the second contained the same promoter sequence except for the + l 3 mutation (A to G transversion; Fig IB) identical to that found in one hemophilia B Leyden patient and was a gift from Dr G.G. Brownlee (University of Oxford, Oxford, UK). The plasmid DNA was isolated by alkaline lysis" and digested with Asp718 and RomHl and the transgene fragment was isolated by gel electrophoresis. The restricted fragment was electroeluted and purified by column chromatography (NAC 52s; GIBCO BRL, Gaithersburg, MD). The identity of the transgene was determined by restriction enzyme digestion and sequencing before insertion into the genome of the mice.
C57BI16J-fertilized eggs were microinjected with the appropriate transgene according to standard procedures,'0 and the injected embryos were transferred to pseudopregnant B6D2/FI females on the day of microinjection. Offspring were weaned at approximately 28 were preserved and -bred with normal C57B1/6 to establish the transgenic lines.
The copy number of the transgenes was determined by Southern blot analysis2' using genomic DNA from transgenic founder mice and several transgenic progeny in each transgenic line. Approximately IO pg of each genomic DNA was digested with PvulI and electrophoresed in 0.8% agarose gels. Transgene copy controls were prepared based on the number of mouse cells represented in IO pg of genomic DNA such that I. 5. 10. and 50 copies per cell were represented as appropriate. Transgene copy control DNA was combined with 10 pp of negative control mouse DNA and digested with Pvull. Standard procedures were followed in preparing DNA for transfer to Nytran membrane. Prehybridization and hybridization were performed using a "P-labeled nick-translated full-length transgene as a probe. After washing. the membrane was used to expose x-ray film with intensifying screens. Hybridizing bands were also counted in a betascope (Betagen, Waltham, MA) before stripping and probing a second time with the murine thyroid-stimulating hormone P-subunit cDNA (TSHB). Counts from the hybridizing bands detected with the TSHB probe were used to correct for differences in loading andor transfer when calculating the number of transgene copies.
PCR prorocol. Standard PCR was performed in 25 pL reaction volume containing 50 to 100 ng of template DNA. For personal use only. on October 27, 2017. by guest www.bloodjournal.org From and a final elongation at 72°C for 2 minutes. The reaction sample was resolved on a 5% polyacrylamide gel. If a particular band was to be analyzed, it was excised, eluted, and purified by column chromatography WAC 52's) using the manufacturer's protocol.
RNA isolation. Total cellular RNA was isolated from fresh or frozen tissue with Tri Reagent (Molecular Research Center, Inc, Cincinnati, OH) using the manufacturer's protocol. The RNA was rehydrated in 100 pL of diethyl pyrocarbonate (DEPC)-treated distilled water, the concentration was determined spectrophotometrically, and the integrity was determined by agarose gel electrophoresis.
Reverse transcription and PCR (RT-PCR).
RT-PCR was performed using a modification of a one tube protocol.'* The initial annealing of the primers to the RNA was in 9 pL of distilled water containing of 1 pg of total RNA and 2.2 prnoVL mouse FIX 3' primer 1256GGACAAG~C'ITAACTGGC1z75 (complementary strand sequence)" and 2.2 pmoVL aldolase 3' primer 686TTATGC-CAGTATCTGCCAGCAGAAT7Io (complementary strand sequence; Genbank accession no. M1 1560), followed by incubation at 65°C for 15 minutes and then at 4°C for 5 minutes. Sixteen units of avian myeloblastosis virus (AMV) reverse transcriptase (Promega) and 40 U of RNasin (Promega) were added to the hybridization mixture; the volume was adjusted to 20 pL with buffer containing 50 mmol/L Tris-HC1, pH 8. pmoVL of each primer, 0.1% Triton X-100, and 2 U of Taq DNA polymerase (Promega). The solution was denatured for 1 minute at 95°C and then an 18-cycle PCR reaction was performed (95°C for 30 seconds, 58°C for 20 seconds, and 72°C for 30 seconds). Identical aliquots (15 pL) of amplified products were resolved on a 5% polyacrylamide gel and dried and the incorporated radioactivity was determined by Betascope analysis (Betagen). Background was subtracted and the ratio of the cpm (FIX) to cpm (aldolase) was calculated. Ratio data from 30 animals (10 sets of animals in 5 age groups: 2 months, 6 months, 8 months, 20 months, and 28 months) were pooled, and the statistical significance of age-related differences in this ratio was analyzed by a one-way analysis of variance (ANOVA). The identity of the amplified products was verified by cycle sequencing method~logy.~~ BOUND ET AL FIX activity measurement. FIX activity in plasma from various ages of mice were measured using an activated partial thromboplastin time (AP'IT)-based assay. Serial dilutions (from 1:5 to 1:160) from normal human plasma (Helena, Beaumont, TX) in Owren's veronal buffer (American Dade, Miami, FL) were used to generate a standard curve. Dilutions (0.1 mL) were mixed with 0.1 mL of FIX-deficient plasma and 0.1 mL of AP'IT reagent (Dade). After 5 minutes of incubation at 37°C 0.1 mL of 0.02 mol/L CaCl, (Dade) was added and the clotting time was measured on an MLA Electra 700 automatic coagulation timer (Medical Laboratory Automation, Inc, Pleasantville, NY). Mouse whole blood was aspirated from the heart under anesthesia and mixed 9:l with 3.2% sodium citrate. Plasma was separated, diluted 1:lO into Owren's veronal buffer, and treated identically to measure FIX levels in mouse blood. The standard curve is based on a 100% FIX activity in normal human plasma.
Analysis oftransgene expression. Approximately 0.05 g of frozen tissue was placed in 200 pL of ice-cold Tris-HC1, pH 7.8, in a 2-mL Eppendorf tube and homogenized with two 15-second bursts by a Brinkman homogenizer (Brinkman Instruments Inc, Westbury, NY) at setting 6. The homogenate was freeze-thawed three times and cellular debris was pelleted at 12,OOOg for 10 minutes at 4°C. The supernatant was incubated at 65°C for 5 minutes and spun at 32,OOOg for 10 minutes at 4°C. The protein concentration of the resulting supernatant was determined using the Bradford assay,3' and the extract was stored at -80°C until use.
Twenty micrograms of crude extract were incubated for 60 minutes at 37°C in 150 pL of total volume containing 0.25 moVL TrisHCl, pH 7.5,530 prnoVL acetyl CoA, and 0.25 pCi of ['4C]-labeled chloramphenicol (56 mCi/mmol; Amersham, Arlington Heights, IL). A second aliquot of acetyl CoA was added and the sample incubated for a second 60-minute period. The resulting mixture was then extracted with 1 mL of ethyl acetate, lyophilized until dry, and then dissolved in 35 pL of ethyl acetate. The samples were spotted onto a 20 X 20 cm silica gel TLC plate (Sigma, St Louis, MO) and run to the top with a 95% chlorofod5% methanol solution. The plate was dried and exposed to Kodak XAR autoradiography film (Eastman Kodak, Rochester, NY) at -80°C. Quantitative data were obtained by subsequent analysis of the radiolabel incorporated into the spots corresponding to the acetylated products of chloramphenicol with the Betascope.
RESULTS
To investigate whether murine FIX mRNA levels increased during aging, we measured relative FIX mRNA levels using RT-PCR in 2-, 6-, 8-, 20-, and 28-month-old mice total liver RNA. Aldolase, a medium to low abundant housekeeping mRNA, showed no significant change with age and was used as an internal standard in RT-PCR analysis. To show that the RT-PCR reactions are quantitative, we have performed the RT-PCR reactions with increasing numbers of PCR cycles and also with increasing quantities of total RNA. For
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The counts per minute (CPM) from the FIX and aldolase linear range at 18 cycles of PCR and for 1 pg total RNA bands were plotted against the number of cycles (Fig 2A) ( Fig 2A and B) . No nonspecific amplifications were observed as well as against the concentration of total RNA (Fig 2B) . under these conditions. This range was in agreement with The results showed that the RT-FCR reactions were in the the earlier report on RT-PCR analysis of aldolase mRNA." 
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We have used the above optimal conditions in our analysis of relative FIX mRNA levels. The ratio of FIX mRNA/ aldolase mRNA was measured in various ages of both male and female mice. A representative gel separation of RT-PCR products derived from liver RNA that was obtained from various ages of male mice is given in Fig 2C. A moderate but significant increase in relative FIX mRNA level between mice (of both sexes) of 2, 6, 8, 20 , and 28 months of age was shown using the RT-PCR procedure. There was no significant difference in FIX mRNA levels between male and female mice of same age (data not shown). Figure 2D shows the cumulative data on relative FIX mRNA levels from both male and female mice of various ages. Because of the low levels of endogenous FIX mRNA, it has been difficult to use nuclear run-on assays to determine if there are age-related changes in the production of newly transcribed FIX mRNA. Hence, we were unable to definitively show that the increase in FIX mRNA levels is due to an increase in FIX mRNA synthesis at the transcriptional level.
To determine if the increase in FIX mRNA levels that is observed between 2-and 28-month-old mice is physiologically relevant, we have used the one-stage clotting assay' to measure FIX activity in 2-and 28-month-old mice of both sexes. Two-month-old male mice showed only SO% to 60% of the FIX activity measured in 28-month-old male mice (Fig 2E) . Female mice also showed similar FIX activity levels as a function of age (data not shown).
Because aged CS7BV6 mice, like humans, show increased levels of FIX activity with age, we wished to determine if the expression of a chimeric construct driven either by the normal human FIX promoter or the mutant Leyden promoter would also manifest age-related changes in the transgenic mouse model. Five transgenic lines were generated that carried the chimeric construct consisting of the -189 to +21 region of the normal human FIX promoter linked to a CAT reporter. Two transgenic lines were generated that carried the same -189 to +21 region of the human FIX promoter but with the Leyden mutation at + 13 position. Three of the founder lines bearing the human normal FIX promoter and one of the lines with the Leyden promoter did not breed or died before the generation of viable offspring. Analysis of the two remaining normal lines, designated N71 and N4II1, and the + 13 mutant line, designated N311, generated the data outlined in the next paragraph. Southern and PCR analysis showed that N4III had incorporated 15 to 20 copies of the transgene into its genome, N71 had incorporated 70 to 80 copies, and N31I had incorporated 5 to 15 copies.
The transgene expression was analyzed by measuring CAT activity in various tissues. A representative CAT activity analysis from N71 animal is shown in Fig 3A. The expression was liver-specific regardless of whether the transgenic lines were expressing CAT activity driven by the human normal FIX promoter or the Leyden promoter (Fig 3B) . The expression of the human FIX promoter's activity was also evaluated throughout the life span of the mouse by analysis of CAT activity in liver extracts from mice of various ages. In the transgenic mice carrying the human normal FIX promoter, no difference in the level of CAT activity was detected in liver extracts (Fig 3B) regardless of age, sex, or founder line. In contrast, liver-specific expression of the Leyden promoter-regulated transgene was detected only in 6-and 8-month-old male mice (Fig 3B) . Liver extracts from 2-and 3-month-old male mice and from 2-and 8-month-old female mice did not display CAT activity. The CAT activity in the liver extracts of 8-month-old Leyden promoter bearing male mice was approximately 50% to 60% of that observed in equal amounts of liver extracts from mice carrying normal FIX promoter of the same age. The liver extracts from 6-month-old animals showed approximately 25% to 30% of the CAT activity observed in normal FIX promoter carrying mice. We have also analyzed 2 animals (18-month-old male and female mice) of the Leyden promoter containing line that did not breed (copy number of transgene unknown). Only the male mouse showed CAT activity (data not shown) comparable to the 8-month-old N3II male mice, but the female mouse did not show any detectable CAT activity. Because this line did not breed, we could not obtain statistically meaningful data. However, the lack of expression in the female mouse was similar to the data collected from N3II female mice.
DISCUSSION
Our data show that FIX mRNA levels and FIX activity increase with increasing age in mice of both sexes. In addition, our results provide the first demonstration that the agerelated increase in FIX activity in mice age can be correlated with a corresponding increase in the level of FIX mRNA. These observations are consistent with the previous demonstration of an increase in FIX activity in humans with aging.' The physiologic significance of this age-related increase in FIX activity is unknown. The developmental expression of murine FIX mRNA begins at day 4 of gestation but is low (< 10% of that found in 2-month-old animals) until just before parturition, at which time it increases dramatically to 40% to 50% of the adult level. This increase continues through 2 months of age, when FIX mRNA levels are reported to stabilize.2 However, until now, neither FIX activity nor FIX mRNA levels have been examined after 2 months of age in mice. Our data complement the work of Yao et a12 and provide a complete description of FIX mRNA levels throughout the life span of the mouse. One clear observation, based on our FIX data and the developmental data of Yao et a1,' is that expression of the murine FIX gene throughout the relative life span of mouse is comparable to that of the human. This finding suggests that the murine hepatocyte may serve as a model for the human system to study the regulation of the FIX gene in vivo.
Our results provide the first demonstration that the The normal FIX promoter-driven transgene did not exhibit any sex-or age-related differences in its expression pattern.
Although equal expression of FIX in both male and female mice is consistent with previous clinical data: some increases in expression of the normal promoter during aging might be expected based on clinical data' and on our own observations (see above). However, no significant changes in the expression of the normal FIX promoter-driven transgene were detectable with aging. On the other hand, the Leyden promoter-driven transgene was expressed in a distinct ageand sex-specific pattern that closely parallels that observed in the human Leyden phenotype. In the human Leyden male patients, FIX activity is between 10% and 20% of normal at 20 years of age and is even lower at puberty. Interestingly, however, FIX activity in these individuals shows a progressive increase with age to reach 50% to 60% of normal in the fifth decade of life." Considering the relative life span of the mouse and human, 2-month-old mice are probably equivalent to 20-year-old individuals and 8-month-old mice
For personal use only. on October 27, 2017. by guest www.bloodjournal.org From are probably equivalent to 50-year-old individuals. In the transgenic animals that carried the fusion gene with the Leyden promoter, we were unable to detect CAT activity at 2 months of age. However, 8-month-old mice presented a clearly demonstrable increase in CAT activity. This is the first demonstration that the + 13 mutation in the -189 to +21 bp FIX promoter segment is capable of generating the Leyden phenotype in a male transgenic mouse model. The failure of female transgenic mice that carry the Leyden promoter to express CAT activity at any age suggests that a male-specific factor may be necessary for the expression of the Leyden phenotype. It also suggests that human females who are carriers for FIX Leyden should have 50% of normal levels throughout life, but this possibility remains to be investigated. Our data are consistent with the previous suggestion of an important role of androgens in the presentation of Leyden phenotype.'','' On the other hand, although puberty in mice occurs at or near 1 month of age and although androgen receptor mRNA and hormone levels have stabilized in 2-month-old male mice,z'~22 the Leyden promoter does not appear to be activated in transgenic mice of this age. Hence, although androgens are apparently essential for the expression of the Leyden phenotype, these steroids do not appear to be sufficient, by themselves, to produce significant promoter activity in transgenic males. From our transgenic data, it appears that an additional factor(s) whose expression or activation commences some time after puberty is also required for mediating the age-related increase in the expression of the Leyden promoter.
It has been recently shown that DBP, a liver-specific DNA-binding protein with a postpubertal expre~sion,~~ may be involved in the regulation of the FIX gene through a specific synergistic interaction with C/EBPa at a binding site -219/-202. It has also been shown that DBP binds weakly to the + 13 mutation site and that the complex of C/ EBPa and DBP binds even better to this site. It is interesting that our +13 mutant promoter does not contain the major 202-219 binding site and still shows age-dependent expression. If the age-dependent increase is in part due to DBP or a complex of C/EBPa and DBP binding to the CEBPa site, it probably participates in the complex protein-protein interactions.
In conclusion, our data have shown that the levels of FIX mRNA in mice increase with age. Furthermore, the mouse model regulates a -189 to +21 bp FIX promoter segment from normal and Leyden FIX genes in a manner analogous to that observed in the human. For personal use only. on October 27, 2017. by guest www.bloodjournal.org From
